Literature DB >> 11036042

RNA polymerase inhibitors with activity against rifampin-resistant mutants of Staphylococcus aureus.

A O'Neill1, B Oliva, C Storey, A Hoyle, C Fishwick, I Chopra.   

Abstract

A collection of rifampin-resistant mutants of Staphylococcus aureus with characterized RNA polymerase beta-subunit (rpoB) gene mutations was cross-screened against a number of other RNA polymerase inhibitors to correlate susceptibility with specific rpoB genotypes. The rpoB mutants were cross-resistant to streptolydigin and sorangicin A. In contrast, thiolutin, holomycin, corallopyronin A, and ripostatin A retained activity against the rpoB mutants. The second group of inhibitors may be of interest as drug development candidates.

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 11036042      PMCID： PMC101622          DOI： 10.1128/AAC.44.11.3163-3166.2000

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  25 in total

Review 1.  Molecular genetic basis of antimicrobial agent resistance in Mycobacterium tuberculosis: 1998 update.

Authors:  S Ramaswamy; J M Musser
Journal:  Tuber Lung Dis       Date:  1998

2.  Molecular characterization of rpoB mutations conferring cross-resistance to rifamycins on methicillin-resistant Staphylococcus aureus.

Authors:  T A Wichelhaus; V Schäfer; V Brade; B Böddinghaus
Journal:  Antimicrob Agents Chemother       Date:  1999-11       Impact factor: 5.191

3.  Molecular evolution of rifampicin resistance in Streptococcus pneumoniae.

Authors:  M Enright; P Zawadski; P Pickerill; C G Dowson
Journal:  Microb Drug Resist       Date:  1998       Impact factor: 3.431

Review 4.  The search for antimicrobial agents effective against bacteria resistant to multiple antibiotics.

Authors:  I Chopra; J Hodgson; B Metcalf; G Poste
Journal:  Antimicrob Agents Chemother       Date:  1997-03       Impact factor: 5.191

5.  RNA polymerase mutants of Escherichia coli. Streptolydigin resistance and its relation to rifampicin resistance.

Authors:  Y Iwakura; A Ishihama; T Yura
Journal:  Mol Gen Genet       Date:  1973-03-01

6.  New approaches to the control of infections caused by antibiotic-resistant bacteria. An industry perspective.

Authors:  I Chopra; J Hodgson; B Metcalf; G Poste
Journal:  JAMA       Date:  1996-02-07       Impact factor: 56.272

7.  Mapping and sequencing of mutations in the Escherichia coli rpoB gene that lead to rifampicin resistance.

Authors:  D J Jin; C A Gross
Journal:  J Mol Biol       Date:  1988-07-05       Impact factor: 5.469

8.  Holomycin and an antibiotic (MM 19290) related to tunicamycin, metabolites of Streptomyces clavuligerus.

Authors:  M Kenig; C Reading
Journal:  J Antibiot (Tokyo)       Date:  1979-06       Impact factor: 2.649

9.  Four contiguous amino acids define the target for streptolydigin resistance in the beta subunit of Escherichia coli RNA polymerase.

Authors:  L M Heisler; H Suzuki; R Landick; C A Gross
Journal:  J Biol Chem       Date:  1993-12-05       Impact factor: 5.157

10.  Inhibition of messenger ribonucleic acid synthesis in Escherichia coli by thiolutin.

Authors:  G G Khachatourians; D J Tipper
Journal:  J Bacteriol       Date:  1974-09       Impact factor: 3.490
View more
  29 in total

1.  Involvement of the beta subunit of RNA polymerase in resistance to streptolydigin and streptovaricin in the producer organisms Streptomyces lydicus and Streptomyces spectabilis.

Authors:  Marina Sánchez-Hidalgo; Luz Elena Núñez; Carmen Méndez; José A Salas
Journal:  Antimicrob Agents Chemother       Date:  2010-02-22       Impact factor: 5.191

2.  Cross-resistance of Escherichia coli RNA polymerases conferring rifampin resistance to different antibiotics.

Authors:  Ming Xu; Yan Ning Zhou; Beth P Goldstein; Ding Jun Jin
Journal:  J Bacteriol       Date:  2005-04       Impact factor: 3.490

3.  Molecular genetic and structural modeling studies of Staphylococcus aureus RNA polymerase and the fitness of rifampin resistance genotypes in relation to clinical prevalence.

Authors:  A J O'Neill; T Huovinen; C W G Fishwick; I Chopra
Journal:  Antimicrob Agents Chemother       Date:  2006-01       Impact factor: 5.191

Review 4.  Structural perspective on mutations affecting the function of multisubunit RNA polymerases.

Authors:  Vincent Trinh; Marie-France Langelier; Jacques Archambault; Benoit Coulombe
Journal:  Microbiol Mol Biol Rev       Date:  2006-03       Impact factor: 11.056

5.  Antimicrobial properties and mode of action of the pyrrothine holomycin.

Authors:  B Oliva; A O'Neill; J M Wilson; P J O'Hanlon; I Chopra
Journal:  Antimicrob Agents Chemother       Date:  2001-02       Impact factor: 5.191

6.  Novel hybrid-type antimicrobial agents targeting the switch region of bacterial RNA polymerase.

Authors:  Fumika Yakushiji; Yuko Miyamoto; Yuki Kunoh; Reiko Okamoto; Hidemasa Nakaminami; Yuri Yamazaki; Norihisa Noguchi; Yoshio Hayashi
Journal:  ACS Med Chem Lett       Date:  2013-01-11       Impact factor: 4.345

7.  The antibiotic sorangicin A inhibits promoter DNA unwinding in a Mycobacterium tuberculosis rifampicin-resistant RNA polymerase.

Authors:  Mirjana Lilic; James Chen; Hande Boyaci; Nathaniel Braffman; Elizabeth A Hubin; Jennifer Herrmann; Rolf Müller; Rachel Mooney; Robert Landick; Seth A Darst; Elizabeth A Campbell
Journal:  Proc Natl Acad Sci U S A       Date:  2020-11-16       Impact factor: 11.205

8.  Mycobacterium tuberculosis is resistant to streptolydigin.

Authors:  Alexander Speer; Jennifer L Rowland; Michael Niederweis
Journal:  Tuberculosis (Edinb)       Date:  2013-04-13       Impact factor: 3.131

9.  Frequency, spectrum, and nonzero fitness costs of resistance to myxopyronin in Staphylococcus aureus.

Authors:  Aashish Srivastava; David Degen; Yon W Ebright; Richard H Ebright
Journal:  Antimicrob Agents Chemother       Date:  2012-09-24       Impact factor: 5.191

10.  In vitro activity of novel rifamycins against rifamycin-resistant Staphylococcus aureus.

Authors:  Christopher K Murphy; Steve Mullin; Marcia S Osburne; John van Duzer; Jim Siedlecki; Xiang Yu; Kathy Kerstein; Michael Cynamon; David M Rothstein
Journal:  Antimicrob Agents Chemother       Date:  2006-03       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.